Company profile
Navidea Biopharmaceuticals, Inc.
OTC: NAVBQ · Healthcare · Biotechnology
#1123 of 1,417 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 52GM —SS 15
v0.1 · 25/100 weight · pillars only
↑ disclosure history, growth stability · ↓ operating margin, net margin
Methodology →Revenue TTM
$610
Rev growth YoY (TTM)
-99.5%
Net income (FY)
-$15.2M
Employees
11
as of 2026-08-29
Market cap
$10.0k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$14.6k$14.6k2022
Net income-$15.2M-$15.2M2022
Operating income-$14.1M-$14.1M2022
Total assets$4.4M$4.4M2022
Liabilities$12.5M$12.5M2022
Equity-$8.4M-$8.4M2022
Revenue trend
FY2015 – FY2022 · USD
FY15
FY16
FY17
FY18
FY19
FY20
FY21
FY22
Revenue by segment
Filed disclosures · FY2022
By product
Grant78%
Royalty22%
By geography
Not disclosed.
The read
What is Navidea Biopharmaceuticals, Inc.’s revenue?
Navidea Biopharmaceuticals, Inc. booked $14.6k in FY2022 revenue, contracting 68% year over year — slower than 86% of Healthcare companies we track, at a -103633.7% net margin.
Peers · Healthcare
Upper Street Marketing Inc.——Pineapple, Inc.——Cardio Diagnostics Holdings, Inc.30DNass Valley Gateway Ltd.——Premier Biomedical, Inc.——Wuhan General Group (China), Inc.——Neighbors
Franklin →Key facts
CEOCraig A. Dais
SectorHealthcare
IndustryBiotechnology
HeadquartersDublin, OH
ExchangeOTC: NAVBQ
Employees11
IPO date2025-09-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.